Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure

Abstract

Reduced circulating apo M is independently associated with adverse outcomes across the spectrum of human heart failure. Further research is needed to assess whether the apo M/S1P axis is a suitable therapeutic target in heart failure.